Christophe Béroud

Christophe Béroud

Auto-generated profile, based on publicly available information

Christophe Béroud

INSERM U827, Laboratoire de Génétique Moleculaire, Montpellier, France

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2009 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
FDFrançois-Olivier Desmet
François-Olivier Desmet
Hamroun DalilHamroun Dalil
Hamroun Dalil
MLMarine Lalande
Marine Lalande
GCGwenaëlle Collod-Béroud
Gwenaëlle Collod-Béroud
MCMireille Claustres
Mireille Claustres
CBChristophe Béroud
Christophe Béroud
Thousands of mutations are identified yearly. Although many directly affect protein expression, an increasing proportion of mutations is now believed to influence mRNA splicing. They mostly affect existing splice sites, but synonymous, non-synonymous or nonsense mutations can also create or disrupt splice sites or auxiliary cis-splicing sequences. To facilitate the analysis of the different mutations, we designed Human Splicing Finder (HSF), a tool to predict the effects of mutations on splicing signals or to identify splicing motifs in any human sequence. It contains all available matrices for auxiliary sequence prediction as well as new ones for binding sites of the 9G8 and Tra2-β Serine-Arginine proteins and the hnRNP A1 ribonucleoprotein. We also developed new Position Weight Matrices to assess the strength of 5′ and 3′ splice sites and branch points. We evaluated HSF efficiency using a set of 83 intronic and 35 exonic mutations known to result in splicing defects. We showed that the mutation effect was correctly predicted in almost all cases. HSF could thus represent a valuable resource for research, diagnostic and therapeutic (e.g. therapeutic exon skipping) purposes as well as for global studies, such as the GEN2PHEN European Project or the Human Variome Project.

21 January 2015 in Human Mutation
Verified
Journal Article
Open access
PDF file
CBCatherine L. Bladen
Catherine L. Bladen
DSDavid Salgado
David Salgado
SMSoledad Monges
Soledad Monges
MFMaria E. Foncuberta
Maria E. Foncuberta
KKKyriaki Kekou
Kyriaki Kekou
HLHanns Lochmüller
Hanns Lochmüller
Analyzing the type and frequency of patient‐specific mutations that give rise to Duchenne muscular dystrophy (DMD) is an invaluable tool for diagnostics, basic scientific research, trial planning, and improved clinical care. Locus‐specific databases allow for the collection, organization, storage, and analysis of genetic variants of disease. Here, we describe the development and analysis of the TREAT‐NMD DMD Global database (http://umd.be/TREAT_DMD/). We analyzed genetic data for 7,149 DMD mutations held within the database. A total of 5,682 large mutations were observed (80% of total mutations), of which 4,894 (86%) were deletions (1 exon or larger) and 784 (14%) were duplications (1 exon or larger). There were 1,445 small mutations (smaller than 1 exon, 20% of all mutations), of which 358 (25%) were small deletions and 132 (9%) small insertions and 199 (14%) affected the splice sites. Point mutations totalled 756 (52% of small mutations) with 726 (50%) nonsense mutations and 30 (2%) missense mutations. Finally, 22 (0.3%) mid‐intronic mutations were observed. In addition, mutations were identified within the database that would potentially benefit from novel genetic therapies for DMD including stop codon read‐through therapies (10% of total mutations) and exon skipping therapy (80% of deletions and 55% of total mutations).

1 December 2001 in Nature Reviews Cancer
Verified
Journal Article
Closed access
TSThierry Soussi
Thierry Soussi
CBChristophe Béroud
Christophe Béroud

1 September 2007 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
LFL. Faivre
L. Faivre
GCG. Collod-Beroud
G. Collod-Beroud
BLBart Loeys
Bart Loeys
ACA. Child
A. Child
CBC. Binquet
C. Binquet
CBCatherine Boileau
Catherine Boileau

20 January 2009 in Human Mutation
Verified
Journal Article
Open access
PDF file
STSylvie Tuffery-Giraud
Sylvie Tuffery-Giraud
CBChristophe Béroud
Christophe Béroud
FLFrance Leturcq
France Leturcq
RYRabah Ben Yaou
Rabah Ben Yaou
Hamroun DalilHamroun Dalil
Hamroun Dalil
MCMireille Claustres
Mireille Claustres
UMD–DMD France is a knowledgebase developed through a multicenter academic effort to provide an up‐to‐date resource of curated information covering all identified mutations in patients with a dystrophinopathy. The current release includes 2,411 entries consisting in 2,084 independent mutational events identified in 2,046 male patients and 38 expressing females, which corresponds to an estimated number of 39 people per million with a genetic diagnosis of dystrophinopathy in France. Mutations consist in 1,404 large deletions, 215 large duplications, and 465 small rearrangements, of which 39.8% are nonsense mutations. The reading frame rule holds true for 96% of the DMD patients and 93% of the BMD patients. Quality control relies on the curation by four experts for the DMD gene and related diseases. Data on dystrophin and RNA analysis, phenotypic groups, and transmission are also available. About 24% of the mutations are de novo events. This national centralized resource will contribute to a greater understanding of prevalence of dystrophinopathies in France, and in particular, of the true frequency of BMD, which was found to be almost half (43%) that of DMD. UMD–DMD is a searchable anonymous database that includes numerous newly developed tools, which can benefit to all the scientific community interested in dystrophinopathies. Dedicated functions for genotype‐based therapies allowed the prediction of a new multiexon skipping (del 45–53) potentially applicable to 53% of the deleted DMD patients. Finally, such a national database will prove to be useful to implement the international global DMD patients' registries under development. Hum Mutat 30:1–12, 2009.

1 April 2014 in Neuromuscular Disorders
Verified
Journal Article
Open access
CBCarsten G. Bönnemann
Carsten G. Bönnemann
CWChing H. Wang
Ching H. Wang
SQSusana Quijano-Roy
Susana Quijano-Roy
NDNicolas Deconinck
Nicolas Deconinck
EBEnrico Bertini
Enrico Bertini
Kathryn N. NorthKathryn N. North
Kathryn N. North
Congenital muscular dystrophies (CMDs) are early onset disorders of muscle with histological features suggesting a dystrophic process. The congenital muscular dystrophies as a group encompass great clinical and genetic heterogeneity so that achieving an accurate genetic diagnosis has become increasingly challenging, even in the age of next generation sequencing. In this document we review the diagnostic features, differential diagnostic considerations and available diagnostic tools for the various CMD subtypes and provide a systematic guide to the use of these resources for achieving an accurate molecular diagnosis. An International Committee on the Standard of Care for Congenital Muscular Dystrophies composed of experts on various aspects relevant to the CMDs performed a review of the available literature as well as of the unpublished expertise represented by the members of the committee and their contacts. This process was refined by two rounds of online surveys and followed by a three-day meeting at which the conclusions were presented and further refined. The combined consensus summarized in this document allows the physician to recognize the presence of a CMD in a child with weakness based on history, clinical examination, muscle biopsy results, and imaging. It will be helpful in suspecting a specific CMD subtype in order to prioritize testing to arrive at a final genetic diagnosis.